Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ: XERS )

4.560 -0.010 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,560,365
Open 4.550
Bid (Size) 4.550 (1)
Ask (Size) 4.560 (1)
Prev. Close 4.570
Today's Range 4.490 - 4.679
52wk Range 1.690 - 4.680
Shares Outstanding 66,497,370
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xeris Biopharma - Possibly The Best Pharma Stock
The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. 
Via Talk Markets
Topics Stocks / Equities
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected. 
Via Stocktwits

Performance

YTD
+31.79%
+31.79%
1 Month
+27.73%
+27.73%
3 Month
+29.91%
+29.91%
6 Month
+59.44%
+59.44%
1 Year
+106.33%
+106.33%

More News

Read More
These stocks are gapping in today's session
Via Chartmill
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Earnings Scheduled For March 6, 2025
Via Benzinga
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in Upcoming Investor Conferences
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
From Xeris Biopharma
Via Business Wire
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Xeris Biopharma Reports Third Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in Upcoming Investor Conferences
From Xeris Biopharma Holdings, Inc.
Via Business Wire
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Xeris Biopharma Reports Second Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces CEO Succession Plan
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.